Alzheimer disease (AD) is a neurodegenerative condition
characterized by functional impairment in memory. This
disease affects more than 27 million people worldwide,
accounting for an annual economic burden of more than
$600 million [1–3]. Deep brain stimulation (DBS) is of
interest as a potential therapeutic option for AD, because it
can directly target and modulate activity of structures implicated
in memory functioning